Hydroxychloroquine for fatty liver disease with inflammation
Part of Digestive system clinical trials.
This trial tests if hydroxychloroquine, a medicine used for other conditions, can reduce liver inflammation in people with fatty liver disease. It aims to help those whose fatty liver has caused ongoing liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with fatty liver by ultrasound or MRI.
- You have had elevated liver enzymes (ALT > 41) for more than 3 months.
- You are not pregnant or breastfeeding.
- You do not have active hepatitis B or C.
- You are not already taking hydroxychloroquine and have no history of eye disease called retinal maculopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking probiotics plus making lifestyle changes can improve fatty liver and metabolic health. You may qualify if you have liver fat and at least one sign of metabolic problems like high blood sugar or high blood pressure.
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
This trial tests a traditional Chinese herbal mixture called 'Longqi Jiangzhi Decoction' for people with non-alcoholic fatty liver disease. It aims to see if the herbs can improve liver health and reduce fat in the liver, possibly offering a gentler treatment option.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study tests whether a supplement called betaine can reduce liver fat and damage in people with a type of fatty liver disease that includes inflammation. Half of the participants will receive betaine, and half will receive a placebo (a pill with no active ingredient).
Hear when a new Steatohepatitis, Nonalcoholic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.